Skip to main content
Fig. 4 | Cancer & Metabolism

Fig. 4

From: Sulfasalazine modifies metabolic profiles and enhances cisplatin chemosensitivity on cholangiocarcinoma cells in in vitro and in vivo models

Fig. 4

Multivariate analysis using Principle Component Analysis (PCA) plot between the control and treatment groups. a Cisplatin and b sulfasalazine treatment could be distinguished from the untreated group in the principal component score chart. This indicates that the metabolic profiling of both was different from that of the untreated control, t [1] and t [2] are scores on PC1 and PC2, respectively. c The components of cisplatin combined with sulfasalazine treatment did not differ when compared with the untreated group and d cisplatin alone

Back to article page